Atomoxetine News and Research RSS Feed - Atomoxetine News and Research

Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2013. Certain financial information for 2013 and 2012 are presented on both a reported and a non-GAAP basis. [More]
Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms. [More]
Study finds increase in use of stimulant medications to treat children and teens with ADHD

Study finds increase in use of stimulant medications to treat children and teens with ADHD

Use of stimulant medications to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents has increased significantly over the past several years. [More]
New DNA chip could improve diagnosis and therapeutics of ADHD

New DNA chip could improve diagnosis and therapeutics of ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is the most common childhood neuropsychiatric disorder. Yet there is currently no tool that will confirm the diagnosis of ADHD. In her thesis entitled "Development of a genotyping system to be applied in Attention Deficit Hyperactivity Disorder and its Pharmacogenetics". [More]
Combination of ADHD drug and parental intervention can help children with autism

Combination of ADHD drug and parental intervention can help children with autism

Researchers at The Ohio State University are conducting a study to determine which is more effective for helping children on the autism spectrum: training parents or taking medication. [More]
Young children more likely to be diagnosed and treated for ADHD

Young children more likely to be diagnosed and treated for ADHD

The youngest children in the classroom are significantly more likely to be diagnosed with attention-deficit/hyperactivity disorder (ADHD) - and prescribed medication - than their peers in the same grade, according to a study just published in CMAJ. [More]
Atomoxetine drug may restore memory deficits in menopausal women

Atomoxetine drug may restore memory deficits in menopausal women

Memory lapses and changes in mental functions occur naturally as we get older. But for many women going through menopause, these memory lapses occur more frequently. [More]
ADHD drugs not bad for the heart: Study

ADHD drugs not bad for the heart: Study

Drugs widely prescribed for attention disorders like Ritalin, Adderall and other drugs, did not increase the risk of serious heart problems in a major study published Monday. This could assure parents of children on these medications on heart-related safety of the medicines. [More]
Parent behavior training can effectively treat ADHD in young children

Parent behavior training can effectively treat ADHD in young children

Formal training in parenting strategies is a low-risk, effective method for improving behavior in preschool-age children at risk for developing attention deficit hyperactivity disorder (ADHD), while there is less evidence supporting the use of medications for children younger than 6 years old, according to a new report from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ). [More]

U.S. appeals court rules in favor of Lilly over Strattera patent case

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has overturned a prior ruling by the U.S. District Court for the District of New Jersey and has upheld the validity of the company's method-of-use patent on Strattera. [More]
Amphetamines can control ADHD symptoms in adults

Amphetamines can control ADHD symptoms in adults

Giving amphetamines to adults with Attention Deficit Hyperactivity Disorder (ADHD) can help them control their symptoms, but the side effects mean that some people do not manage to take them for very long. [More]
Eli Lilly 2010 third-quarter total revenue increases 2% to $5.655 billion

Eli Lilly 2010 third-quarter total revenue increases 2% to $5.655 billion

Eli Lilly and Company today announced financial results for the third quarter of 2010.Financial results for 2010 and 2009 are presented on both a reported and a non-GAAP basis. [More]

FDA approves Atomoxetine HCl capsules for ADHD

Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD). [More]
USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules. [More]
Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Eli Lilly and Company today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera. In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly's '590 patent, or method-of-use patent, for Strattera is invalid. The patent had been set to expire in May of 2017. [More]
FDA approves Strattera for ADHD in children and adolescents

FDA approves Strattera for ADHD in children and adolescents

Eli Lilly and Company announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults. [More]
Growth in ADHD medication use due to improved ADHD identification in adult and female patients

Growth in ADHD medication use due to improved ADHD identification in adult and female patients

Attention deficit hyperactivity disorder (ADHD) has been traditionally viewed as a childhood disorder, while ADHD in adults has been underdiagnosed and undertreated. [More]
UIC study evaluates two medications for ADHD

UIC study evaluates two medications for ADHD

University of Illinois at Chicago researchers are comparing two drugs commonly used to treat attention deficit hyperactivity disorder to determine if genetic factors predict which children will respond to either or both drugs. [More]

New advice about the use of Strattera (atomoxetine)

New advice to doctors and patients about the use of Strattera, (atomoxetine), was issued today by the Medicines and Healthcare products Regulatory Agency, (MHRA). [More]
Treatment with Strattera makes children with ADHD fall asleep faster

Treatment with Strattera makes children with ADHD fall asleep faster

Twice daily treatment with Strattera® (atomoxetine HCl), approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), showed children with ADHD fell asleep faster compared to three-times daily treatment with methylphenidate [More]